Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Michael R. Bourque"'
1
SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS
Autor: Maria Petrecz, Susan K. Bradshaw, Kim M. Strohmaier, Theoklis E. Zaoutis, Michael R. Bourque, Arlene Taylor, Johan Maertens, Angela L. Ngai, Andreas H. Groll, Nicholas A. Kartsonis, William J. Steinbach, Thomas Lehrnbecher, Hasan S. Jafri, Joseph W. Chow
Publikováno v: Pediatric Infectious Disease Journal. 28:1132-1135
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bf271284f10ca2001d0307ed542094
https://doi.org/10.1097/inf.0b013e3181af5a15
Zobrazit plný text záznamu
2
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis
Autor: Lawrence Serfaty, Peggy Hwang, Maribel Rodriguez-Torres, Eric Lawitz, Michael R. Bourque, Julie Strizki, Richard J. O. Barnard, Mark J. DiNubile, S. Bhanja, Albrecht Stoehr, Niloufar Mobashery, Amy Zhou, Edward Gane
Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 12(6)
Background & Aims The combination of vaniprevir (a NS3/4A protease inhibitor) with peginterferon and ribavirin was shown to increase rates of sustained virologic response (SVR) significantly, compared with peginterferon and ribavirin alone, in treatm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e30f067c3aeb835c72bb26ecbef83aa
https://pubmed.ncbi.nlm.nih.gov/24120953
Zobrazit plný text záznamu
3
Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report
Autor: Michael R. Bourque, Nicholas A. Kartsonis, Robert J. Lupinacci, Angela L. Ngai, Kim M. Strohmaier
Publikováno v: International journal of antimicrobial agents. 38(6)
Safety experience is available from 32 completed clinical studies (17 Phase I and 15 Phase II–III) of caspofungin (CAS) conducted between 1995 and 2010 in adult and paediatric patients. Clinical and laboratory adverse events (AEs) were collected fr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ab03a1e56a0be0aa82fa0a00ad6944
https://pubmed.ncbi.nlm.nih.gov/21925846
Zobrazit plný text záznamu
4
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia
Autor: Johan A, Maertens, Luis, Madero, Anne F, Reilly, Thomas, Lehrnbecher, Andreas H, Groll, Hasan S, Jafri, Michael, Green, Joseph J, Nania, Michael R, Bourque, Beth Ann, Wise, Kim M, Strohmaier, Arlene F, Taylor, Nicholas A, Kartsonis, Joseph W, Chow, Carola A S, Arndt, Ben E, DePauw, Thomas J, Walsh
Publikováno v: Pediatric Infectious Disease Journal, 29, 415-20
Pediatric Infectious Disease Journal, 29, 5, pp. 415-20
Contains fulltext : 87474.pdf (Publisher’s version ) (Closed access) BACKGROUND: Persistently febrile neutropenic children at risk for invasive fungal infections receive empiric antifungal therapy as a standard of care. However, little is known abo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d0c0582164234bace9a8304a8eb84d
http://hdl.handle.net/2066/87474
Zobrazit plný text záznamu
6
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
Autor: Hedy Teppler, Thomas J. Walsh, Lindsey R. Baden, Michael R. Bourque, Oliver A. Cornely, Carole A. Sable, Gerald R. Donowitz, Robert J. Lupinacci, Ben E. dePauw, Anna Dmoszynska, Johan Maertens
Publikováno v: The New England Journal of Medicine, 351, 1391-1402
The New England Journal of Medicine, 351, 14, pp. 1391-1402
Patients with persistent fever and neutropenia often receive empirical therapy with conventional or liposomal amphotericin B for the prevention and early treatment of invasive fungal infections. Caspofungin, a member of the new echinocandin class of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6b62869ee120b947efd25bc8c97fe2
https://doi.org/10.1056/NEJMoa040446
Zobrazit plný text záznamu
8
Empirical Antifungal Therapy (Rx) with Caspofungin (CAS) vs Liposomal Amphotericin B (L-AmB) for Persistently Febrile Neutropenic Patients (Pts) with Acute Myeloid Leukemia (AML)
Autor: Robert J. Lupinacci, Hedy Teppler, Carole A. Sable, Johan Maertens, Mark J. DiNubile, Michael R. Bourque
Publikováno v: Blood. 104:1337-1337
Background: In a double-blind randomized trial of empirical antifungal Rx for persistently febrile neutropenic pts, CAS was as effective as and better tolerated than L-AmB. We now examine the results of this study in the subgroup of pts with AML. Met
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c87923fa689d8332490e13067b221a3
https://doi.org/10.1182/blood.v104.11.1337.1337
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje